HER2+ Breast Cancer

HER2+ Breast Cancer

Closing the Gaps in Current Treatment

Not a member of My prIME? Join now for instant access.

Meeting Overview

Get the latest updates in HER2+ breast cancer at this interactive satellite symposium. A variety of topics will be discussed, including challenges in the management of HER2+ breast cancer, new and emerging agents in both the adjuvant and metastatic settings, and unmet medical needs. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

Official EBCC-11 Sponsored Satellite Symposium #EBCC11

Date and Location

Thursday, 22 March 2018
13.00 – 14.15

Room: Picasso (113-116)
Centre de Convencions Internacional de Barcelona (CCIB)
Plaça de Willy Brandt, 11-14
Barcelona, Spain



Thursday, 22 March 2018
13.00 – 14.15



Barcelona, Spain



13.00 Welcome and introduction
Sibylle Loibl, MD, PhD
13.02 HER2+ early breast cancer: Clinical options
Sibylle Loibl, MD, PhD
13.05 HER2+ breast cancer: Remaining challenges after 20 years of trastuzumab
Suzette Delaloge, MD, MSc
13.20 Q & A
13.25 Adjuvant treatment for HER2+ breast cancer: When is trastuzumab not enough?
Wolfgang Janni, MD, PhD
13.40 Q & A
13.45 Metastatic HER2+ breast cancer: Clinical options
Sibylle Loibl, MD, PhD
13.50 Metastatic HER2+ breast cancer: The search for further treatment improvements
Pierfranco Conte, MD
14.05 Clinical case discussion
Sibylle Loibl, MD, PhD, and Faculty
14.13 prIME Points™
Sibylle Loibl, MD, PhD
14.15 Adjourn


  • Sibylle Loibl, MD, PhDGerman Breast Group, Neu-Isenburg
    Centre for Haematology and Oncology Bethanien
    Frankfurt, Germany
  • Faculty

  • Pierfranco Conte, MDIstituto Oncologico Veneto
    University of Padua
    Padua, Italy
  • Suzette Delaloge, MD, MScGustave Roussy
    Villejuif, France
  • Wolfgang Janni, MD, PhDUniversity of Ulm
    Ulm, Germany

This educational activity is specifically designed for oncologists and other healthcare professionals interested in and/or involved in the treatment of breast cancer who wish to understand some of the latest developments in treatments for patients with HER2+ breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
  • Select the optimal HER2-targeted strategies to improve outcomes for patients with HER2+ breast cancer in the early and metastatic settings
  • Assess new and emerging treatment options for patients with metastatic HER2+ breast cancer

This educational activity is supported by a grant from Puma Biotechnology.

Independent Medical Education

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.